Determinants of anti-PD1 response and resistance in clear cell renal cell carcinoma
Lewis Au(Royal Marsden NHS Foundation Trust), Samra Turajlic(Royal Marsden NHS Foundation Trust), Steve Hazell(Royal Marsden NHS Foundation Trust), Gordon Beattie(Cancer Research UK), Nicos Fotiadis(Royal Marsden NHS Foundation Trust), Ignazio Puccio(University College Hospital), Sergio A. Quezada(Memorial Sloan Kettering Cancer Center), Kevin Litchfield(Cancer Research UK), Désirée Schnidrig(The Francis Crick Institute), Roberto Salgado(Institut Jules Bordet), Charles Swanton(The Francis Crick Institute), Ehsan Ghorani(CRUK Lung Cancer Centre of Excellence), Lisa Pickering(Royal Marsden Hospital), Annika Fendler(The Francis Crick Institute), Emine Hatipoglu(Royal Marsden NHS Foundation Trust), Elaine Borg(University College Hospital), Kim Dhillon(University College Hospital), Benny Chain(University College Lahore), Mary Falzon, José I. López(BioCruces Health research Institute), Mariana Werner Sunderland(London Cancer), Mariam Jamal‐Hanjani(CRUK Lung Cancer Centre of Excellence), Tom Lund(Royal Marsden Hospital), Anna Green(St Thomas' Hospital), Marc Robert de Massy(Cancer Research UK), Andrew Rowan(Cancer Institute (WIA)), Robert M. Mason(Royal Marsden NHS Foundation Trust), George Kassiotis(The Francis Crick Institute), Fiona Byrne(The Francis Crick Institute), Ayse U. Akarca(Cancer Research UK), David A. Moore(The Francis Crick Institute), Kroopa Joshi(Royal Marsden NHS Foundation Trust), Imran Uddin(Cancer Research UK), Miriam Mitchison(Royal London Hospital), Jan Attig(The Francis Crick Institute), James Larkin(Trinity College Dublin), Pablo D. Becker(United Therapeutics (United Kingdom)), R. Houston Thompson(The Francis Crick Institute), Ula Mahadeva(St Thomas' Hospital), Ian Proctor, William Yang(University College Hospital), James L. Reading(CRUK Lung Cancer Centre of Excellence), Hang Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), David Nicol(Royal Stoke University Hospital), Scott Shepherd(The Francis Crick Institute), Andrew Furness(Royal Marsden NHS Foundation Trust), Stuart Horswell(The Francis Crick Institute), Marcos Duran Vasquez(Cancer Research UK), Teresa Marafioti(Cancer Research UK)
Cited by 28
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k